Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

GANX stock hub

Gain Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

GANXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

77.6M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

GANX

In the news

Latest news · GANX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.6P50 18.3P75 33.7

Trailing P/En/a

P25 15P50 23.3P75 38.5

ROE-155.7

P25 -106.6P50 -46.9P75 -3.1

ROIC-85.8

P25 -63.1P50 -27.5P75 -0

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All GANX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001819411
Company name	Gain Therapeutics, Inc.
Country	United States
Country code	US
Cusip	36269B105
Employees	21
Employees Change	-4%
Employees Change Percent	-16
Enterprise value	$57.5M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-03-18
Isin	US36269B1052
Last refreshed	2026-05-10
Market cap	$77.6M
Market cap category	Micro-Cap
Price	$1.82
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	GANX
Website	https://gaintherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-25.97%
FCF yield	-23.79%
P/B ratio	4.12x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-10.1M
Net Income	$-20.2M
Net Income Growth Years	2%
Profit Per Employee	$-960,052
ROA	-67.01
Roa5y	-57.16
ROCE	-96.22
ROE	-155.7
Roe5y	-127.1
ROIC	-85.8

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-6.67%
Cagr3y	-30.83%
Cagr5y	-29.57%
EPS Growth Years	2
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$22.8M
Cash	$20.8M
Current Assets	$22.2M
Current Liabilities	$3.4M
Debt	$732,067
Debt Equity	$0.04
Equity	$18.6M
Liabilities	$4.3M
Long Term Assets	$581,837
Long Term Liabilities	$901,831
Net Cash	$20.1M
Net Cash By Market Cap	$25.9
Net Cash Growth	106.57%
Net Debt Equity	$-1.08
Tangible Book Value	$18.5M
Tangible Book Value Per Share	$0.44
WACC	5.05

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	6.63
Net Working Capital	$-1.7M
Quick ratio	6.46
Working Capital	$18.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-44.08%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-6.67%
200-day SMA	2.18
3Y total return	-66.91%
50-day SMA	2.12
50-day SMA vs 200-day SMA	50under200
5Y total return	-82.67%
All Time High	17.93
All Time High Change	-89.85%
All Time High Date	2021-04-12
All Time Low	0.89
All Time Low Change	104.49%
All Time Low Date	2024-08-13
ATR	0.13
Beta	0.15
Beta1y	1.77
Beta2y	1.9
Ch YTD	-43.48
High	1.89
High52	4.34
High52 Date	2025-12-11
High52ch	-58.06%
Low	1.81
Low52	1.41
Low52 Date	2025-08-01
Low52ch	29.08%
Ma50ch	-13.99%
Premarket Change Percent	1.07
Premarket Price	$1.89
Premarket Volume	389
Price vs 200-day SMA	-16.63%
RSI	42.82
RSI Monthly	43.72
RSI Weekly	45.04
Sharpe ratio	0.47x
Sortino ratio	0.75
Total Return	-44.08%
Tr YTD	-43.48
Tr1m	-1.62%
Tr1w	-3.19%
Tr3m	4%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$6
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.14
Operating Income	$-18.7M
Price target	$7.5
Price Target Change	$312
Price Target Change Top	$230

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	41,645,311%
Float Percent	97.64%
Net Borrowing	-96,501
Shares Insiders	2.36%
Shares Institutions	20.29%
Shares Out	42,654,038
Shares Qo Q	8.06%
Shares Yo Y	44.08%
Short Float	8%
Short Ratio	4.68
Short Shares	7.81

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-20.3M
Average Volume	533,768.95x
Bv Per Share	0.44
Ch1m	-1.62
Ch1w	-3.19
Ch1y	-6.67
Ch3m	4
Ch3y	-66.91
Ch5y	-82.67
Ch6m	-7.14
Change	-2.67%
Change From Open	-1.62
Close	1.87
Days Gap	-1.07
Depreciation Amortization	45,046
Dollar Volume	615,125.4
Earnings Date	2026-05-22
Earnings Time	bmo
EBIT	$-18.7M
EBITDA	$-18.7M
EPS	$-0.61
F Score	3
FCF	$-18.5M
FCF EV Yield	-32.1x
FCF Per Share	$-0.43
Financing CF	28,447,766
Fiscal Year End	December
Founded	2,017
Income Tax	$861,118
Ipr	-83.45
Iprfo	-83.78
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-26
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-26
Ma150	2.35
Ma150ch	-22.39%
Ma20	1.94
Ma20ch	-6.38%
Net CF	10,456,366
Next Earnings Date	2026-05-22
Open	1.85
Optionable	Yes
Position In Range	12.66
Post Close	1.82
Postmarket Change Percent	2.2
Postmarket Price	$1.86
Ppne	409,006
Pre Close	1.87
Price Date	2026-05-08
Ptbv Ratio	4.2
Relative Volume	0.63x
Share Based Comp	1,803,195
Tr6m	-7.14%
Us State	Maryland
Volume	337,981

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does GANX pay a dividend?

Capital-return profile for this ticker.

Performance

GANX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns GANX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+20.3%

Float: +97.6% of shares outstanding

Insider ownership

+2.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

GANX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

42.8

Neutral momentum band

Price vs 200-day MA

-16.6%

50/200-day relationship not available

Beta (5Y)

0.15

Less volatile than the market

Sharpe ratio

0.47

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About GANX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current GANX stock rating?

Gain Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GANX analysis?

The full report lives at /stocks/GANX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for GANX?

The latest report frames GANX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the GANX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.